Simplified insulin pump for type II diabetics

Information

  • Patent Grant
  • 11364340
  • Patent Number
    11,364,340
  • Date Filed
    Thursday, February 7, 2019
    5 years ago
  • Date Issued
    Tuesday, June 21, 2022
    a year ago
Abstract
A simplified insulin pump allows type II diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a type II diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.
Description
FIELD OF THE INVENTION

The present invention relates to insulin pumps for the treatment of diabetes and, more particularly to a simplified insulin pump for use by Type II diabetics.


BACKGROUND

There are many applications in academic, industrial, and medical fields that benefit from devices and methods that are capable of accurately and controllably delivering fluids, such as liquids and gases that have a beneficial effect when administered in known and controlled quantities. Such devices and methods can be particularly useful in the medical field where treatments for many patients include the administration of a known amount of a substance at predetermined intervals.


Insulin-injecting pumps have been developed for the administration of insulin for those suffering from both type I and type II diabetes. Recently, continuous subcutaneous insulin injection and/or infusion therapy with portable infusion devices has been adapted for the treatment of diabetes. Such therapy may include the regular and/or continuous injection or infusion of insulin into the skin of a person suffering from diabetes, and offers an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. Such pumps can be ambulatory/portable infusion pumps that are worn by the user and that may use replaceable cartridges. Examples of such pumps and various features that can be associated with such pumps include those disclosed in U.S. patent application Ser. No. 13/557,163, U.S. patent application Ser. No. 12/714,299, U.S. patent application Ser. No. 12/538,018, U.S. Provisional Patent Application No. 61/655,883, U.S. Provisional Patent Application No. 61/656,967 and U.S. Pat. No. 8,287,495, each of which is incorporated herein by reference.


Current infusion pumps typically allow for delivery of two infusion types—a basal rate and a bolus delivery. A basal rate typically delivers insulin at a constant rate over an extended period of time and is provided to maintain target glucose levels throughout the day when a user is not eating. Boluses are delivered to counteract carbohydrates consumed at meal times to maintain target glucose levels. For a meal bolus, for example, the user may enter the amount of carbohydrates the user is about to ingest and the user's carbohydrate ratio (the volume of insulin programmed to be delivered for every particular number of carbohydrates predicted to be consumed by the user). Based on this information, the infusion pump will generate an estimate of a bolus amount of insulin to be delivered. If accepted by the user, e.g., by entering a command such as by depressing a button, touching an object on a touchscreen, etc., the then-current basal delivery mode is suspended and the bolus delivery is initiated.


Careful management of insulin delivery in view of carbohydrate consumption, physical activity, and other factors is critical in maintaining the health of type I diabetics. While delivery of insulin is equally important for the overall health of type II diabetics, the specific timing of the delivery and the precise matching of the amount of insulin to carbohydrates consumed is not as critical. In addition, type II diabetics are generally diagnosed only after years of not having to deal with monitoring carbohydrate intake, taking insulin injections, etc., as opposed to type I diabetics who are usually diagnosed at a much younger age. As a result of these and other factors, type II diabetics often do not have the motivation and/or the willingness to diligently monitor their carbohydrate intake, insulin levels, etc. as is required to properly use most insulin pumps.


Therefore, there is a need for an insulin pump and method that is simplified for the treatment of type II diabetics to provide a needed amount of insulin without requiring precise tracking and matching of carbohydrate intake with insulin delivered.


SUMMARY OF THE INVENTION

A simplified insulin pump allows type II diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a type II diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.


In an embodiment, a portable insulin pump includes a delivery mechanism for delivering insulin to a user and a user interface to display operating parameters of the delivery mechanism and receive input from the user. A processor of the pump receives user input data defining a recurring meal bolus scheduled for delivery at a predetermined time on a type or category of day, such as a weekday. The processor provides an alert to the user through the user interface that a meal bolus is scheduled at the predetermined time on each day in the category of day and then causes the delivery mechanism to deliver the meal bolus to the user.


Certain embodiments are described further in the following description, examples, claims, and drawings. These embodiments will become more apparent from the following detailed description when taken in conjunction with the accompanying exemplary drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an infusion pump according to an embodiment of the present invention.



FIG. 2 is a block diagram representing an embodiment of an infusion pump.



FIG. 3 depicts a screen shot of a home screen page of a graphical user interface of an infusion pump according to an embodiment of the present invention.



FIG. 4 depicts a flowchart of a method of delivering a bolus of insulin according to an embodiment of the present invention.





DETAILED DESCRIPTION

Provided herein are systems, devices and methods for operating an infusion pump and particularly an insulin pump. Some embodiments may include advances in the internal components, the control circuitry, and improvements in a user interface of the systems and devices. The advances may allow for a safer and more accurate delivery of medicament to a patient than is currently attainable today from other devices, systems, and methods. Although embodiments described herein may be discussed in the context of the controlled delivery of insulin, delivery of other medicaments, including, for example, glucagon, pramlintide, etc., as well as other applications are also contemplated. Device and method embodiments discussed herein may be used for pain medication, chemotherapy, iron chelation, immunoglobulin treatment, dextrose or saline IV delivery, or any other suitable indication or application. Non-medical applications are also contemplated.



FIG. 1 depicts an embodiment of a pump 12 such as an infusion pump that can include an internal pumping or delivery mechanism and reservoir for delivering medicament such as insulin to a patient and an output/display 44. The type of output/display 44 may vary as may be useful for a particular application. The type of visual output/display may include LCD displays, LED displays, plasma displays, OLED displays and the like. The output/display 44 may also be an interactive or touch sensitive screen 46 having an input device such as, for example, a touch screen comprising a capacitive screen or a resistive screen. The pump 12 may additionally include a keyboard or other input device known in the art for data entry, which may be separate from the display. The output/display 44 of the pump 12 may also include a capability to operatively couple to a secondary display device such as a laptop computer, mobile communication device such as a smartphone or personal digital assistant (PDA) or the like. Further details regarding such pump devices can be found in U.S. Patent Application No. 2011/0144586, which is incorporated herein by reference.



FIG. 2 illustrates a block diagram of some of the features that may be incorporated within the housing 26 of the pump 12. The pump 12 includes a processor 42 that functions to control the overall functions of the device. The infusion pump 12 may also include a memory device 30, a transmitter/receiver 32, an alarm 34, a speaker 36, a clock/timer 38, an input device 40, the processor 42, a user interface suitable for accepting input and commands from a user such as a caregiver or patient, a drive mechanism 48, and an estimator device 52. One embodiment of a user interface as shown in FIG. 2 is a graphical user interface (GUI) 60 having a touch sensitive screen 46 with input capability. The memory device 30 may be coupled to the processor 42 to receive and store input data and to communicate that data to the processor 42. The input data may include user input data and non-user/sensor input data. The input data from the memory device 30 may be used to generate therapeutic parameters for the infusion pump 12. The GUI 60 may be configured for displaying a request for the user to input data and for receiving user input data in response to the request, and communicating that data to the memory.


The processor 42 may communicate with and/or otherwise control the drive mechanism, output/display, memory, a transmitter/receiver and other components. In some embodiments, the processor 42 may communicate with a processor of another device, for example, a continuous glucose monitor (CGM), through the transmitter/receiver. The processor 42 may include programming that can be run to control the infusion of insulin or other medicament from the cartridge, the data to be displayed by the display, the data to be transmitted via the transmitter, etc. The processor 42 may also include programming that may allow the processor to receive signals and/or other data from an input device, such as a sensor that may sense pressure, temperature or other parameters. The processor 42 may determine the capacity of the drug delivery reservoir and/or the volume of fluid disposed in the drug delivery reservoir and may set therapeutic parameters based on its determination.


The processor 42 may also include additional programming to allow the processor 42 to learn user preferences and/or user characteristics and/or user history data. This information can be utilized to implement changes in use, suggestions based on detected trends, such as, weight gain or loss. The processor can also include programming that allows the device to generate reports, such as reports based upon user history, compliance, trending, and/or other such data. Additionally, infusion pump device embodiments of the disclosure may include a “power off” or “suspend” function for suspending one or more functions of the device, such as, suspending a delivery protocol, and/or for powering off the device or the delivery mechanism thereof. For some embodiments, two or more processors may be used for controller functions of the infusion pump devices, including a high power controller and a low power controller used to maintain programming and pumping functions in low power mode, in order to save battery life.


The memory device 30 may be any type of memory capable of storing data and communicating that data to one or more other components of the device, such as the processor. The memory may be one or more of a Flash memory, SRAM, ROM, DRAM, RAM, EPROM and dynamic storage, for example. For instance, the memory may be coupled to the processor and configured to receive and store input data and/or store one or more template or generated delivery patterns. For example, the memory can be configured to store one or more personalized (e.g., user defined) delivery profiles, such as a profile based on a user's selection and/or grouping of various input factors, past generated delivery profiles, recommended delivery profiles, one or more traditional delivery profiles, e.g., square wave, dual square wave, basal and bolus rate profiles, and/or the like. The memory can also store, for example, user information, history of use, glucose measurements, compliance and an accessible calendar of events.


The housing 26 of the pump 12 may be functionally associated with an interchangeable and a removable glucose meter 20 and/or infusion cartridge 16. The infusion cartridge 16 may have an outlet port 54 that may be connected to an infusion set (not shown) via an infusion set connector 18. Further details regarding some embodiments of various infusion pump devices can be found in U.S. Patent Application No. 2011/0144586, which is hereby incorporated by reference.


Referring to FIG. 3, a front view of the pump 12 is depicted. The pump 12 may include a user interface, such as, for example, a user-friendly GUI 60 on a front surface 58 or other convenient location of the pump 12. The GUI 60 may include a touch-sensitive screen 46 that may be configured for displaying data, facilitating data entry by a patient, providing visual tutorials, as well as other interface features that may be useful to the patient operating the pump 12.


In order to simplify the use of the pump 12 for Type II diabetic patients, the device can be designed so that insulin is delivered with minimal patient interaction. In one embodiment, boluses intended to cover carbohydrates consumed at meal times can be automatically delivered in fixed quantities at fixed times. The user therefore can receive the bolus insulin without having to count the carbohydrates in the meals or remember to enter the carbohydrates to initiate a bolus. As noted above, strict accuracy in carbohydrate consumption and corresponding insulin delivery is not generally required for Type II diabetics, and therefore such a simplified system can be employed.



FIG. 4 depicts a flowchart of a method of delivering a bolus of insulin 200 according to an embodiment of the present invention. Initially, a bolus is programmed into the pump 12 and saved into memory 30 at step 202. The bolus can be for a fixed amount, such as ten units of insulin, and at a fixed time or time period. The bolus can also be associated with a category of day on which it is to be given, such as on all weekdays or all Mondays. When the fixed time or the beginning of the time period is reached on an associated day, such as 8:00 a.m., the bolus can be announced to the user at step 204. The announcement can comprise an alert including one or more of an audio, visual or tactile indication. Alternatively, the bolus can automatically be delivered without reminding the user.


In some embodiments, the user can confirm the bolus at step 206. Additionally, the user may be able to modify the bolus. Such modifications can include, for example, a change in the volume of the bolus or a delay in delivery of the bolus. The user may also be able to cancel the bolus. If the user confirms the bolus, the bolus is delivered to the user at step 208 and the system reverts to step 204 the next time that the time fixed time or beginning of the time period occurs. Alternatively, the bolus may be automatically delivered to the user following the announcement unless the user positively acts to cancel or change the delivery of the bolus. Thus, rather than the user confirming the bolus to have it delivered, the user must affirmatively cancel the bolus to prevent it from being automatically delivered.


The pump may provide for multiple boluses of the same or different amounts at different times during any given day to be stored in memory. In one embodiment, three boluses are stored for each day, corresponding to an approximate breakfast time, lunch time, and dinner time. Boluses can be stored so that different amounts and/or timing of boluses can be set for weekdays and weekends or for each day of the week. A user may also be able to select a bolus schedule according to certain activities or conditions, such as when the user is sick or has a regularly occurring athletic activity. Thus, once the fixed bolus amounts and times are programmed into the device, no further user interaction with the device is required to determine the timing and amount of bolus deliveries regardless of the timing and size (i.e., number of carbohydrates) of the user's actual meals.


In some embodiments, each bolus can be delivered as an extended bolus. Thus, if the user expects to have lunch around noon on a given day, the bolus can, for example, be delivered as an extended bolus between the hours of 11:00 a.m. and 1:00 p.m. Such an extended bolus therefore helps account for variability in meal times while still being delivered with minimal-to-no user interaction. With such an extended bolus, the user also has the option of editing the bolus while it is being delivered to, for example, add insulin for an increased amount of carbohydrates than usual or decrease or cancel a remainder of the bolus if a smaller than usual meal is eaten. Alternatively, boluses may be delivered all at once at a specified meal time, such as noon. Further detail regarding bolus delivery that can be done with pumps as described herein can found in U.S. patent application Ser. No. 13/800,387 “System and Method for Maximum Insulin Pump Bolus Override” by Walsh.


In another embodiment, the standard meal boluses delivered to the user can be incorporated into a basal rate. Thus, for users that already receive a continuous infusion of insulin as a basal rate, the bolus can be incorporated into that basal rate rather than being delivered in addition to the basal rate around meal times. The user's regular basal rate insulin needs and fixed meal bolus amounts can be combined to calculate an adjusted basal rate that is increased to factor in the meal bolus amounts. Such a protocol ensures the user is receiving enough insulin while further reducing interactions the user must make with the device. As noted herein, such a system is feasible for type II diabetic users because the timing of delivery of insulin relative to meal times is not as critical as with type I users. With such a system, the pump need only be programmed initially and no further user interaction with the device is required until the insulin cartridge needs to be changed with a cartridge having a full insulin reservoir, or if the user desires to change the rate of the insulin being delivered. If the user wishes to modify the new basal rate for any reason, a temporary rate can be delivered.


Some embodiments of an infusion system may include a portable infusion device, as described above and a remote commander device. In such an instance, the portable infusion device may include a suitably configured receiver and/or transmitter for communication with an external device such as a remote commander, as well as programming for directing the use of the device; and the remote commander may additionally include a suitably configured receiver and/or transmitter for communication with an external device such as a portable infusion device, as well as programming for directing the use of the device. For instance, the remote commander may include one or more of the functionalities described herein above with respect to the portable infusion device.


For example, the remote commander may include a processor, a memory, a transmitter and/or receiver, an input mechanism, an output mechanism, e.g., a display, a clock, a timer, an alarm, an estimator, and the like. Hence, in certain embodiments, the portable infusion device may include a transmitter that receives commands, e.g., infusion commands, from the processor and transmits the commands (e.g., to a remote commander or vice-versa). Similarly, the remote commander may include a transmitter that receives commands, e.g., infusion commands, from its processor and transmits the commands (e.g., to a portable infusion device or vice-versa). In such an instance, the portable infusion device and/or remote commander may also include a receiver that receives commands, such as remotely/wirelessly generated commands, and communicates the commands to the processor. Accordingly, the remote commander may include the appropriate hardware and software necessary for producing these functionalities in the remote commander, such as that described above with respect to the portable infusion device. The portable infusion device itself or the remote commander may also include programming that includes an initiating command request, whereby the user has to interact with the device, such as by tapping a screen, e.g., on a display of the portable infusion device or remote commander, so as to accept an infusion recommendation before the remote commander signals the portable infusion device and/or before the portable infusion device accepts the command and begins infusion of the fluid.


Some embodiments of the portable infusion device may also include multiple other capabilities in addition to delivering one or more medicaments (i.e., insulin). For example, the portable infusion device may be capable of interacting with a personal computer (PC) for uploading and downloading data, various file types (e.g., JPEG, PDF) and programs. The portable infusion device may also access and send information wirelessly to a PC or other electronic device (e.g., printer, memory storage device). These functions, for example, may be particularly beneficial to a user for sending and receiving information to a physician, or uploading new or upgrading current programs onto the portable infusion device. Furthermore, the portable infusion device may have instructions, or accessible by the user and/or processor for converting information on the device into various file formats, e.g., portable document format (PDF), word processing documents, JPEG, etc., which may be distributed and shared among various electronic devices. The GUI of the portable infusion device assists in improving the usability of at least these capabilities. In addition, some GUI embodiments may be available to a user by downloading a software application onto the user's cell phone and/or PDA, which would allow the user to use their cell phone or PDA as a remote commander to the portable infusion device.


With regard to the above detailed description, like reference numerals used therein may refer to like elements that may have the same or similar dimensions, materials, and configurations. While particular forms of embodiments have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the embodiments herein. Accordingly, it is not intended that the invention be limited by the forgoing detailed description.


The entirety of each patent, patent application, publication, and document referenced herein is hereby incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these documents.


Modifications may be made to the foregoing embodiments without departing from the basic aspects of the technology. Although the technology may have been described in substantial detail with reference to one or more specific embodiments, changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the technology. The technology illustratively described herein may suitably be practiced in the absence of any element(s) not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation and use of such terms and expressions do not exclude any equivalents of the features shown and described or portions thereof and various modifications are possible within the scope of the technology claimed. Although the present technology has been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be made, and such modifications and variations may be considered within the scope of this technology.

Claims
  • 1. A method of providing insulin therapy to a user of an ambulatory insulin pump, comprising: receiving user input defining a meal bolus, the meal bolus comprising a recurring meal bolus of a single fixed amount of all of the insulin configured to counteract an anticipated increase in glucose level as a result of carbohydrates consumed in a meal to be delivered at a predetermined meal time without matching the single fixed amount with a number of carbohydrates consumed in a specific meal;automatically providing an alert to the user that the meal bolus is scheduled for delivery at the predetermined meal time; andcausing an operation to be initiated to deliver all of the meal bolus to the user with the ambulatory infusion pump in a single continuous delivery operation occurring over a time period including the predetermined meal time.
  • 2. The method of claim 1, further comprising receiving a confirmation in response to the alert and wherein causing an operation to be initiated to deliver all of the meal bolus to the user includes causing the operation to be initiated only after receiving the confirmation.
  • 3. The method of claim 1, further comprising receiving a modification to the meal bolus in response to the alert and wherein causing an operation to be initiated to deliver all of the meal bolus to the user includes causing the operation to be initiated to deliver the meal bolus as modified.
  • 4. The method of claim 1, wherein causing an operation to be initiated to deliver all of the meal bolus to the user includes waiting a predetermined period of time after providing the alert and causing the operation to be initiated if the delivery is not cancelled by the user within the predetermined period of time.
  • 5. The method of claim 1, further comprising associating the recurring meal bolus with a category of day.
  • 6. The method of claim 1, wherein the single continuous delivery operation delivers the meal bolus as an extended bolus.
  • 7. The method of claim 1, wherein the single continuous delivery operation delivers all of the meal bolus starting at the predetermined meal time.
  • 8. The method of claim 1, wherein receiving user input defining a meal bolus receives the user input and automatically providing an alert provides the alert with a user interface of the ambulatory insulin pump.
  • 9. The method of claim 1, wherein receiving user input defining a meal bolus receives the user input and automatically providing an alert provides the alert with a user interface of a remote commander configured to remotely control the ambulatory insulin pump.
  • 10. The method of claim 9, wherein the remote commander is a phone.
  • 11. A method of providing insulin therapy to a user of an ambulatory insulin pump, comprising: storing a meal bolus in memory, the meal bolus comprising a recurring meal bolus of a single fixed amount of all of the insulin configured to counteract an anticipated increase in glucose level as a result of carbohydrates consumed in a meal to be delivered at a predetermined meal time without matching the single fixed amount with a number of carbohydrates consumed in a specific meal; andcausing an operation to be initiated to deliver all of the meal bolus to a user with the ambulatory infusion pump in a single continuous delivery operation occurring over a time period including the predetermined meal time.
  • 12. The method of claim 11, further comprising providing an alert to the user that the meal bolus is scheduled for delivery at the predetermined meal time.
  • 13. The method of claim 12, further comprising receiving a confirmation in response to the alert and wherein causing an operation to be initiated to deliver all of the meal bolus to the user includes causing the operation to be initiated only after receiving the confirmation.
  • 14. The method of claim 12, further comprising receiving a modification to the meal bolus in response to the alert and wherein causing an operation to be initiated to deliver all of the meal bolus to the user includes causing the operation to be initiated to deliver the meal bolus as modified.
  • 15. The method of claim 12, wherein causing an operation to be initiated to deliver all of the meal bolus to the user includes waiting a predetermined period of time after providing the alert and causing the operation to be initiated if the delivery is not cancelled by the user within the predetermined period of time.
  • 16. The method of claim 12, wherein providing an alert provides the alert with a user interface of the ambulatory insulin pump.
  • 17. The method of claim 11, wherein the single continuous delivery operation delivers the meal bolus as an extended bolus.
  • 18. The method of claim 11, wherein the single continuous delivery operation delivers all of the meal bolus starting at the predetermined meal time.
  • 19. The method of claim 11, wherein providing an alert provides the alert with a user interface of a remote commander configured to remotely control the ambulatory insulin pump.
  • 20. The method of claim 19, wherein the remote commander is a phone.
RELATED APPLICATION

This application is a continuation of application Ser. No. 13/800,595 filed Mar. 13, 2013, which is hereby fully incorporated herein by reference.

US Referenced Citations (269)
Number Name Date Kind
2462596 Bent Feb 1949 A
2629376 Pierre et al. Feb 1953 A
2691542 Chenoweth Oct 1954 A
3059639 Blackman et al. Oct 1962 A
4469481 Kobayashi Sep 1984 A
5395326 Haber et al. Mar 1995 A
5919216 Houben et al. Jul 1999 A
6034054 Defelippis et al. Mar 2000 A
6471689 Joseph et al. Oct 2002 B1
6544212 Galley et al. Apr 2003 B2
6551276 Mann et al. Apr 2003 B1
6551992 Defelippis et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558351 Steil et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6571128 Lebel et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6648821 Lebel et al. Nov 2003 B2
6668196 Villegas et al. Dec 2003 B1
6740072 Starkweather et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6744350 Blomquist Jun 2004 B2
6810290 Lebel et al. Oct 2004 B2
6827702 Lebel et al. Dec 2004 B2
6852104 Blomquist Feb 2005 B2
6862466 Ackerman Mar 2005 B2
6872200 Mann et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6906028 Defelippis et al. Jun 2005 B2
6936029 Mann et al. Aug 2005 B2
6958705 Lebel et al. Oct 2005 B2
6974437 Lebel et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
6998387 Goke et al. Feb 2006 B1
6999854 Roth Feb 2006 B2
7025743 Mann et al. Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7041082 Blomquist et al. May 2006 B2
7109878 Mann et al. Sep 2006 B2
7204823 Estes et al. Apr 2007 B2
7258864 Clark Aug 2007 B2
7267665 Steil et al. Sep 2007 B2
7354420 Steil et al. Apr 2008 B2
7402153 Steil et al. Jul 2008 B2
7442186 Blomquist Oct 2008 B2
7497827 Brister et al. Mar 2009 B2
7510544 Vilks et al. Mar 2009 B2
7515060 Blomquist Apr 2009 B2
7517530 Clark Apr 2009 B2
7547281 Hayes et al. Jun 2009 B2
7569030 Lebel et al. Aug 2009 B2
7572789 Cowen et al. Aug 2009 B2
7642232 Green et al. Jan 2010 B2
7651489 Estes et al. Jan 2010 B2
7674485 Bhaskaran et al. Mar 2010 B2
7678071 Lebel et al. Mar 2010 B2
7678762 Green et al. Mar 2010 B2
7678763 Green et al. Mar 2010 B2
7704226 Mueller, Jr. et al. Apr 2010 B2
7711402 Shults et al. May 2010 B2
7734323 Blomquist et al. Jun 2010 B2
7751907 Blomquist Jul 2010 B2
7756722 Levine et al. Jul 2010 B2
7766831 Essenpreis et al. Aug 2010 B2
7780981 Dipierro et al. Aug 2010 B2
7785313 Mastrototaro Aug 2010 B2
7806886 Kanderian, Jr. et al. Oct 2010 B2
7815602 Mann et al. Oct 2010 B2
7819843 Mann et al. Oct 2010 B2
7831310 Lebel et al. Nov 2010 B2
7837647 Estes et al. Nov 2010 B2
7850641 Lebel et al. Dec 2010 B2
7905859 Bynum et al. Mar 2011 B2
7920907 McGarraugh et al. Apr 2011 B2
7976870 Berner et al. Jul 2011 B2
8012119 Estes et al. Sep 2011 B2
8062249 Wilinska et al. Nov 2011 B2
8105268 Lebel et al. Jan 2012 B2
8119593 Richardson et al. Feb 2012 B2
8133197 Blomquist et al. Mar 2012 B2
8152789 Starkweather et al. Apr 2012 B2
8206350 Mann et al. Jun 2012 B2
8208984 Blomquist et al. Jun 2012 B2
8219222 Blomquist Jul 2012 B2
8221345 Blomquist Jul 2012 B2
8250483 Blomquist Aug 2012 B2
8257300 Budiman et al. Sep 2012 B2
8287487 Estes Oct 2012 B2
8287495 Michaud et al. Oct 2012 B2
8298184 Diperna et al. Oct 2012 B2
8311749 Brauker et al. Nov 2012 B2
8337469 Eberhart et al. Dec 2012 B2
8344847 Moberg et al. Jan 2013 B2
8346399 Blomquist Jan 2013 B2
8348886 Kanderian, Jr. et al. Jan 2013 B2
8348923 Kanderian, Jr. et al. Jan 2013 B2
8414523 Blomquist et al. Apr 2013 B2
8454510 Yodfat et al. Jun 2013 B2
8454576 Mastrototaro et al. Jun 2013 B2
8454581 Estes et al. Jun 2013 B2
8465460 Yodfat et al. Jun 2013 B2
8573027 Rosinko et al. Nov 2013 B2
8657779 Blomquist Feb 2014 B2
8712748 Thukral Apr 2014 B2
8753316 Blomquist Jun 2014 B2
8775877 McVey et al. Jul 2014 B2
8882701 Debelser et al. Nov 2014 B2
8938306 Lebel Jan 2015 B2
8986253 Diperna Mar 2015 B2
8992475 Mann Mar 2015 B2
9008803 Blomquist Apr 2015 B2
9114210 Estes Aug 2015 B2
9474856 Blomquist Oct 2016 B2
9492608 Saint Nov 2016 B2
9603995 Rosinko et al. Mar 2017 B2
9737656 Blomquist Aug 2017 B2
9940441 Walsh Apr 2018 B2
10016561 Saint et al. Jul 2018 B2
10049768 Blomquist Aug 2018 B2
10201656 Rosinko Feb 2019 B2
20020016568 Lebel Feb 2002 A1
20020019606 Lebel Feb 2002 A1
20020065454 Lebel May 2002 A1
20020107476 Mann Aug 2002 A1
20030055406 Lebel Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163223 Blomquist Aug 2003 A1
20030163789 Blomquist Aug 2003 A1
20030212364 Mann et al. Nov 2003 A1
20040193090 Lebel et al. Sep 2004 A1
20050022274 Campbell et al. Jan 2005 A1
20050143864 Blomquist Jun 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050272640 Doyle Dec 2005 A1
20060173406 Hayes Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20070016170 Kovelman Jan 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070066956 Finkel Mar 2007 A1
20070112298 Mueller, Jr. et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070161955 Bynum et al. Jul 2007 A1
20070287985 Estes et al. Dec 2007 A1
20080033357 Mann et al. Feb 2008 A1
20080071580 Marcus et al. Mar 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080114299 Damgaard-Sorensen May 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080147050 Mann et al. Jun 2008 A1
20080171697 Jacotot et al. Jul 2008 A1
20080171967 Blomquist et al. Jul 2008 A1
20080172026 Blomquist Jul 2008 A1
20080172027 Blomquist Jul 2008 A1
20080172028 Blomquist Jul 2008 A1
20080172029 Blomquist Jul 2008 A1
20080172030 Blomquist Jul 2008 A1
20080172031 Blomquist Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080183060 Steil et al. Jul 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080300534 Blomquist Dec 2008 A1
20090006129 Thukral Jan 2009 A1
20090036753 King Feb 2009 A1
20090163855 Shin et al. Jun 2009 A1
20090177142 Blomquist et al. Jul 2009 A1
20090177147 Blomquist et al. Jul 2009 A1
20090247931 Damgaard-Sorensen Oct 2009 A1
20090275886 Blomquist et al. Nov 2009 A1
20100008795 Diperna Jan 2010 A1
20100094251 Estes Apr 2010 A1
20100114015 Kanderian, Jr. et al. May 2010 A1
20100125241 Prud et al. May 2010 A1
20100145262 Bengtsson et al. Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100160740 Cohen et al. Jun 2010 A1
20100161236 Cohen et al. Jun 2010 A1
20100161346 Getschmann et al. Jun 2010 A1
20100174266 Estes Jul 2010 A1
20100174553 Kaufman et al. Jul 2010 A1
20100185142 Kamen et al. Jul 2010 A1
20100185175 Kamen et al. Jul 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100198520 Breton et al. Aug 2010 A1
20100218132 Soni et al. Aug 2010 A1
20100249530 Rankers et al. Sep 2010 A1
20100249561 Patek et al. Sep 2010 A1
20100262117 Magni et al. Oct 2010 A1
20100262434 Shaya Oct 2010 A1
20100274592 Nitzan et al. Oct 2010 A1
20100280329 Randloev et al. Nov 2010 A1
20100286653 Kubel et al. Nov 2010 A1
20100292634 Kircher, Jr. et al. Nov 2010 A1
20100305545 Kanderian, Jr. et al. Dec 2010 A1
20100324382 Cantwell et al. Dec 2010 A1
20110006876 Moberg et al. Jan 2011 A1
20110009725 Hill et al. Jan 2011 A1
20110009813 Rankers Jan 2011 A1
20110021898 Wei et al. Jan 2011 A1
20110033833 Blomquist et al. Feb 2011 A1
20110040251 Blomquist et al. Feb 2011 A1
20110054390 Searle et al. Mar 2011 A1
20110054391 Ward et al. Mar 2011 A1
20110071464 Palerm Mar 2011 A1
20110071765 Yodfat Mar 2011 A1
20110098637 Hill Apr 2011 A1
20110098638 Chawla et al. Apr 2011 A1
20110098674 Vicente et al. Apr 2011 A1
20110106011 Cinar et al. May 2011 A1
20110106050 Yodfat et al. May 2011 A1
20110112505 Starkweather et al. May 2011 A1
20110112506 Starkweather et al. May 2011 A1
20110118578 Timmerman May 2011 A1
20110124996 Reinke et al. May 2011 A1
20110125095 Lebel et al. May 2011 A1
20110130746 Budiman Jun 2011 A1
20110137239 Debelser et al. Jun 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110144616 Michaud et al. Jun 2011 A1
20110152770 Diperna et al. Jun 2011 A1
20110152824 Diperna et al. Jun 2011 A1
20110160695 Sigrist et al. Jun 2011 A1
20110166544 Verhoef et al. Jul 2011 A1
20110184264 Galasso et al. Jul 2011 A1
20110196213 Thukral et al. Aug 2011 A1
20110256024 Cole et al. Oct 2011 A1
20120013625 Blomquist et al. Jan 2012 A1
20120013802 Blomquist et al. Jan 2012 A1
20120029433 Michaud et al. Feb 2012 A1
20120029468 Diperna Feb 2012 A1
20120030610 Diperna et al. Feb 2012 A1
20120041415 Estes et al. Feb 2012 A1
20120059353 Kovatchev et al. Mar 2012 A1
20120220939 Yodfat Aug 2012 A1
20120226124 Blomquist Sep 2012 A1
20120232484 Blomquist Sep 2012 A1
20120232485 Blomquist Sep 2012 A1
20120232520 Sloan et al. Sep 2012 A1
20120232521 Blomquist Sep 2012 A1
20120238854 Blomquist Sep 2012 A1
20120265722 Blomquist Oct 2012 A1
20120277667 Yodat et al. Nov 2012 A1
20120302991 Blomquist Nov 2012 A1
20120330227 Budiman et al. Dec 2012 A1
20130046281 Javitt Feb 2013 A1
20130053816 Diperna et al. Feb 2013 A1
20130131630 Blomquist May 2013 A1
20140276420 Rosinko Sep 2014 A1
20140276531 Walsh Sep 2014 A1
20140276553 Rosinko et al. Sep 2014 A1
20140276556 Saint et al. Sep 2014 A1
20140276574 Saint Sep 2014 A1
20150182693 Rosinko Jul 2015 A1
20150182695 Rosinko Jul 2015 A1
20150217044 Blomquist Aug 2015 A1
20150314062 Blomquist et al. Nov 2015 A1
20160082188 Blomquist et al. Mar 2016 A1
20170165416 Saint Jun 2017 A1
20170246380 Rosinko et al. Aug 2017 A1
20170312423 Rosinko Nov 2017 A1
20180133397 Estes May 2018 A1
20180133398 Blomquist May 2018 A1
20180137252 Mairs May 2018 A1
20180226145 Walsh Aug 2018 A1
20180233221 Blomquist Aug 2018 A1
20180361060 Rosinko Dec 2018 A9
Foreign Referenced Citations (6)
Number Date Country
399065 Jul 1924 DE
19819407 Nov 1999 DE
WO-03082091 Oct 2003 WO
WO-2007065944 Jun 2007 WO
WO-2009016636 Feb 2009 WO
WO-2013184896 Dec 2013 WO
Non-Patent Literature Citations (3)
Entry
Application and File History for U.S. Appl. No. 13/800,595, filed Mar. 13, 2013, inventors Saint.
International Preliminary Reporton Patentability for Application No. PCT/US2014/021075, dated Sep. 24, 2015, 12 pages.
International Search Report for Application No. PCT/US2014/021075, dated Jul. 1, 2014, 24 pages.
Related Publications (1)
Number Date Country
20190167901 A1 Jun 2019 US
Continuations (1)
Number Date Country
Parent 13800595 Mar 2013 US
Child 16269767 US